

Utility of Salivary Cortisol Measurements in Cushing's Syndrome and Adrenal Insufficiency

Hershel Raff

Endocrine Research Laboratory, Aurora St. Luke's Medical Center, Milwaukee, Wisconsin 53215; and Division of Endocrinology, Metabolism, and Clinical Nutrition, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

Context: The measurement of cortisol in saliva is a simple, reproducible, and reliable test to evaluate the normal and disordered control of the hypothalamic-pituitary-adrenal (HPA) axis. There are a variety of simple methods to obtain saliva samples without stress, making this a robust test applicable to many different experimental and clinical situations.

Evidence Acquisition: Ovid Medline and PubMed from 1950 to present were searched using the following strategies: [<saliva or salivary>and<cortisol or hydrocortisone>and<Cushing or Cushing's>] and [<saliva or salivary>and<cortisol or hydrocortisone>and<adrenal insufficiency or hypoadrenalism or hypopituitarism or Addison's disease>]. The bibliographies of all relevant citations were evaluated for any additional appropriate citations.

Evidence Synthesis: Measurement of an elevated late-night (2300 to 2400 h) salivary cortisol has a greater than 90% sensitivity and specificity for the diagnosis of endogenous Cushing's syndrome. Late-night salivary cortisol measurements are also useful to monitor patients for remission and/or recurrence after pituitary surgery for Cushing's disease. Because it is a surrogate for plasma free cortisol, the measurement of salivary cortisol may be useful during an ACTH stimulation test in patients with increased plasma binding protein concentrations due to increased estrogen, or decreased plasma binding protein concentrations during critical illness. Most reference laboratories now offer salivary cortisol testing.

Conclusions: It is expected that the use of the measurement of salivary cortisol will become routine in the evaluation of patients with disorders of the HPA axis. (*J Clin Endocrinol Metab* 94: 3647–3655, 2009)

One of the hallmarks of the hypothalamic-pituitary-adrenal (HPA) axis is its central role in the stress response (1). As a result, clinical evaluation of the HPA axis is predicated on the notion that biochemical assessment should be performed in a low-stress environment, particularly when increases in cortisol secretion are suspected. In most situations, a typical blood draw does bring with it some degree of stress, particularly in children. Therefore, less invasive techniques have been developed, including the 24-h collection of urine for the measurement of free cortisol. A major advance in assessing the dynamics of

the HPA axis in a low-stress environment is the measurement of salivary cortisol.

Salivary cortisol measurements have been in use since the 1960s. The majority of studies published using salivary cortisol involved its application to studying the stress response and psychoneuroendocrinology, rather than for the clinical evaluation of patients (2, 3). An Ovid Medline search of <saliva or salivary>and<cortisol or hydrocortisone> for 1950 to March 2009 yielded 2433 citations, including 1247 citations with a further focus on "stress." It is beyond the scope of this review to discuss the large

number of studies that used salivary cortisol measurements to examine the stress response. Suffice it to say that acquiring samples of saliva for the analysis of cortisol is a robust and accessible technique that can be applied to almost any experimental scenario.

The Ovid Medline search described above was refined to focus on salivary cortisol and Cushing's syndrome, yielding 104 citations, and on salivary cortisol and adrenal insufficiency, yielding 25 citations. Recently, there has been a rapid increase in interest in the use of salivary cortisol measurements for the diagnosis of disorders of the HPA axis highlighted by several recent reviews (4–11). This Clinical Review will focus on newer studies using salivary cortisol measurements in the diagnosis of Cushing's syndrome and in the evaluation of adrenal insufficiency.

Methodological Considerations

The biologically active component of the HPA axis is plasma free cortisol that is in equilibrium with salivary cortisol (8). There are a variety of approaches to obtain saliva for the measurement of cortisol, including expectation, passive drool, aspiration (particularly in infants), and chewing on a cotton or polyester swab using commercial devices (8). The method of obtaining saliva can affect the assessment of steroids including cortisol, so the reference ranges established should be internally consistent with the sampling method (12–15). Saliva obtained from a commercially available cotton sampling device like the Salivette, which is easy to use and transport, appears to give salivary cortisol results that are very reliable predictors of total and free plasma cortisol levels (16).

There are several potential preanalytical errors in acquiring samples for salivary cortisol including contamination of the sample by the patient with over-the-counter hydrocortisone creams and ointments. Remember that hydrocortisone is authentic cortisol and cannot be distinguished from endogenous cortisol, even using analysis with chromatography and mass spectrometry. Also, the timing of the sampling is usually critical, and it is documented that compliance with this requirement can be less than optimal (17). Because patients often obtain saliva samples at home, the clinician should always carefully explain to the patient the importance of the timing of the sample as well as confirm that sampling was done correctly when the results are interpreted. It is fortunate that cortisol is stable in saliva at room temperature for at least a week, and samples can be mailed to the laboratory by standard postal service (18–20). Although blood contamination of saliva may alter other analyte concentrations,

there seems to be no or a minimal effect on the measurement of salivary cortisol (21).

There are several methods for the measurement of cortisol in saliva. These include RIA, ELISA, platform immunoassays, and liquid chromatography/tandem mass spectrometry (LC/TMS) (4, 8, 11, 15, 22–26). Each approach has its pluses and minuses. In actuality, under most circumstances, any of these assay methods generally performs well. The advantages of immunoassays are that they detect many cortisol metabolites, are simple and inexpensive to run, and require small volumes of saliva. The disadvantage is the potential to cross-react with synthetic steroids like prednisone. LC/TMS avoids this problem. However, TMS may miss the patient with factitious Cushing's syndrome unless synthetic steroids are analyzed in every sample. Occult factitious Cushing's syndrome was detected in samples referred to my laboratory because of very high salivary cortisol levels detected by ELISA that were subsequently confirmed by LC/TMS for synthetic steroids and by the clinicians reinterviewing the patients. It is also important to point out again that TMS cannot distinguish between endogenous cortisol and contamination from hydrocortisone in over-the-counter ointments and creams, although an increased ratio of cortisol to cortisone in the sample may suggest contamination. Because immunoassays are standard in most laboratories and LC/TMS requires expensive and sophisticated equipment, immunoassays are usually acceptable as long as the caveats described above are kept in mind. Each methodology generates a different reference range, so it is vital that clinicians carefully interpret salivary cortisol results, taking into consideration the laboratory and method used particularly because there is no external proficiency-testing scheme or certified reference material currently available to harmonize assays (27).

There is a misconception that it is difficult for clinicians to obtain a salivary cortisol measurement for their patients through their clinical laboratory or institution. In fact, most, if not all reference laboratories now offer this test, although the methods used and reference ranges generated vary. Furthermore, a Food and Drug Administration-cleared ELISA, which is simple and inexpensive to perform, is commercially available (28). Therefore, there is no impediment to evaluating salivary cortisol in patients in the United States.

Cushing's Syndrome

The diagnosis of endogenous Cushing's syndrome is among the most difficult in clinical endocrinology. The phenotype is very common in the population, and the frequency of the disorder is relatively uncommon. Therefore,

accurate, convenient, and relatively inexpensive screening tests are paramount if the large number of patients with suspected Cushing's syndrome can be evaluated. The comparison of the performance of the commonly used diagnostic tests for Cushing's syndrome has been extensively reviewed, and a detailed discussion of the comparison of these tests is beyond the scope of this review (1, 6, 7, 10, 29–34). Briefly, the standard approaches are the overnight low-dose dexamethasone suppression test, 24-h urine free cortisol, and late-night salivary cortisol measurement. All of these tests have potential pluses and minuses, but the general consensus is that late-night salivary cortisol has the highest sensitivity, whereas the low-dose dexamethasone suppression test can have the best specificity, depending on the serum cortisol cutoff used. Because these different tests evaluate different dynamic components of the HPA axis, it is advocated that they be used in concert to complement each other (4, 34).

Overt Cushing's syndrome

The circadian rhythm is another hallmark of the HPA axis. Because the failure to achieve a normal nadir between 2300 and 0100 h is characteristic of Cushing's syndrome, assessment of an elevated late-night or midnight cortisol level was initially shown to have a very high sensitivity and specificity when blood was sampled in sleeping patients under very controlled circumstances to reduce ambient stress (35, 36). This approach is highly impractical for most clinicians, so sampling for salivary cortisol has been advocated as a useful surrogate for blood sampling for cortisol.

One of the first studies demonstrating the feasibility of using salivary cortisol measurements late at night for the clinical evaluation of endogenous hypercortisolism was in 1984 by Evans *et al.* (37) who demonstrated a dampening of the circadian rhythm and an elevation of midnight salivary cortisol in patients with Cushing's syndrome. They also demonstrated that assessment of salivary cortisol in the morning sample after an overnight dexamethasone suppression test is useful. The usefulness of a combination of the measurement of late-night salivary cortisol and a morning, dexamethasone-suppressed salivary cortisol to improve specificity has been confirmed by others (38–40).

Since the studies of Evans *et al.* in the 1980s, many studies have been published demonstrating a high sensitivity and specificity of late-night salivary cortisol measurements for Cushing's syndrome (Table 1). It is important to note that the number of cases and controls, the diagnostic criteria, the types of controls, the assay methodologies, the methods used to generate cut points, and the saliva sampling techniques varied between studies listed in this table. Even so, it is remarkable that these differences

TABLE 1. Studies of late-night salivary cortisol measurement in the diagnosis of Cushing's syndrome

First author, year (Ref.)	Sensitivity	Specificity
Adults		
Luthold, 1985 (89)	100%	100%
Laudat, 1988 (69)	100%	100%
Raff, 1998 (65)	92%	97%
Castro, 1999 (39)	93%	93%
Papanicolaou, 2002 (90)	95%	100%
Putignano, 2003 (91)	93%	93%
Yaneva, 2004 (92)	100%	94%
Trilck, 2005 (93)	98%	96%
Viardot, 2005 (94)	100%	100%
Baid, 2007 (23)	ND	85%, ^a 92% ^b
Vilar, 2008 (95)	100%	ND
Restituto, 2008 (43)	88%	82%
Doi, 2008 (96)	93%	100%
Nunes, 2009 (44)	100%	100%
Cardoso, 2009 (40)	100%	98%
Yaneva, 2009 (97)	93%	94%
Children		
Martinelli, 1999 (41)	100%	95%
Gafni, 2000 (42)	93%	100%

ND, Not done.

^a Radioimmunoassay.

^b LC/TMS.

do not appear to be particularly important because most studies found similar sensitivities and specificities for Cushing's syndrome of more than 90%. It should also be noted that saliva sampling is particularly useful in children suspected of Cushing's syndrome in whom blood and urine sampling can be a challenge (41, 42).

Since our most recent comprehensive review of the literature (4), several papers have been published that should be considered. Restituto *et al.* (43) showed a lower sensitivity and specificity for Cushing's syndrome than most other studies (Table 1). Although a precise reason for this could not be pinpointed, it is noteworthy in this study that a midnight, sleeping serum cortisol yielded a sensitivity of only 50%, which is much lower than the seminal studies originally describing this approach (35, 36). One explanation may be the use of receiver operating characteristic curves to calculate sensitivity and specificity, whereas earlier studies used reference ranges and arbitrary cutoffs to do so. It is also noteworthy that the cutoffs for midnight levels in the study of Restituto *et al.* (43) were 291 nmol/liter (10.5 μ g/dl) for serum cortisol, which is higher than previously found (36), and 2.2 nmol/liter (0.08 μ g/dl) for salivary cortisol, which is lower than previously found using the same assay (25, 28). There may be something different about the general approach of Restituto *et al.* (43) in addition to the use of receiver operating characteristic curves that yielded lower diagnostic utility for late-night cortisol sampling whether in blood or saliva.

One of the possible problems using late-night salivary cortisol is the potential for a lower specificity for

Cushing's syndrome. This could be due to difficulties in reproducibility of the sample in patients with mild Cushing's syndrome as well as proximate stress in patients without Cushing's syndrome. This was recently studied by Cardoso *et al.* (40) who found an intraclass coefficient of variation of 0.89 in patients with Cushing's syndrome and 0.83 in control patients between two late-night salivary cortisol samples taken 48 h apart. This suggests that variation of two salivary cortisol measurements in the same patient is 17% or less. Considering that the assay used had an intraassay coefficient of variation of about 6%, and that normal subjects have low salivary cortisol levels at which assays generally do not perform as well as at higher concentrations, a biological variability of 17% is excellent. However, one can imagine that one of two samples could be abnormal in someone without Cushing's but with higher physiological HPA axis activity, and one of two samples could be normal in a patient with mild Cushing's syndrome. Nunes *et al.* (44) found a calculated concordance correlation coefficient by regression of approximately 0.65 for outpatients, suggesting a lower reproducibility than that of Cardoso *et al.* (40). We recently demonstrated that late-night salivary cortisol levels can be elevated in as few as 14% of the samples in patients with proven but very mild Cushing's syndrome (45). Interestingly, 24-h urine free cortisol was consistently normal in several of these patients. Only persistence and a high index of clinical suspicion can allow the accurate diagnosis of these challenging patients. It has been my experience that waiting 1 or 2 months and then repeating the salivary cortisol measurement often resolves a false-positive, discordant result.

A lower specificity of late-night salivary cortisol could also be due to other factors increasing late-night salivary cortisol in patients without Cushing's syndrome. Just about any stressor proximal to obtaining a late-night saliva sample could theoretically lead to a false-positive result, as could differences in lifestyle (46). For example, a recent study demonstrated that elderly male veterans with type 2 diabetes mellitus had an increased frequency of false-positive salivary cortisol results (47). Much of this may have been due to the population studied that included patients with difficult living situations, abnormal sleep patterns, and prior addiction problems. Another potential source of error is the venue at which the samples are obtained. Despite this concern, Nunes *et al.* (44) recently demonstrated a high concordance between late-night saliva samples obtained on the same patients in the inpatient *vs.* outpatient setting.

We recently published a meta-analysis of the performance of salivary cortisol for the diagnosis of Cushing's syndrome using the publications through 2007 shown in




FIG. 1. A paradigm using salivary cortisol as the initial test to evaluate patients with suspected Cushing's syndrome (adapted from Ref. 4). oDST, Overnight 1 mg dexamethasone suppression test; UFC, 24-h urine free cortisol.

Table 1 (48). A total of 947 patients (339 with Cushing's syndrome) were identified in the seven studies that met the stringent criteria for meta-analysis. The sensitivity of late-night salivary cortisol for Cushing's syndrome was 92%, the specificity was 96%, and the diagnostic odds ratio was 312. This analysis establishes late-night salivary cortisol measurement as one of the primary methods of choice in general clinical practice to screen any patient suspected of Cushing's syndrome.

It is recommended that two late-night salivary cortisol tests be performed 24–48 h apart as the initial testing for Cushing's syndrome (Fig. 1). If they are both normal, Cushing's syndrome is excluded with about 90–95% certainty. If they are both above the reference range, Cushing's syndrome is proven with about 90–95% certainty. However, before a patient is subjected to a differential diagnostic workup, it is prudent to confirm the diagnosis with complementary testing such as the dexamethasone suppression test and 24-h urine free cortisol measurement. It is also prudent to carefully interview the patient for any factors that could have caused a physiological increase in cortisol release as well as to confirm that the samples were obtained at the correct time and without contamination. If the two salivary cortisol results are discordant, they can be repeated, or complementary testing can be performed.

Subclinical Cushing's syndrome

With the advent of CT scanning for general abdominal complaints, it has been found that adrenal neoplasms are common and some actually secrete cortisol autonomously. The Cushingoid signs and symptoms are usually few or absent, and only biochemical testing reveals subtle

increases in cortisol secretion. This so-called subclinical Cushing's syndrome is now well documented, although there does not appear to be a consensus as to how this syndrome is defined (49–53). As one might expect, the performance of any test (including salivary cortisol) in the evaluation of subclinical Cushing's syndrome is less effective than in the diagnosis of overt Cushing's syndrome. The cutoff for an abnormal late-night salivary cortisol concentration had to be lowered, and, even then, the sensitivity and specificity was only about 90% in one study, which also showed that the overnight 1 mg dexamethasone suppression test may be an alternative of choice (44). A recent study, which also used other abnormal endocrine tests to establish subclinical Cushing's syndrome, found a much poorer performance with a sensitivity of only 23% and a specificity of 88% (54). Therefore, a normal late-night salivary cortisol concentration clearly does not rule out subclinical Cushing's syndrome (55).

Postsurgical follow-up

It is well known that recurrence of pituitary tumors in patients with Cushing's disease after pituitary surgery is fairly common (56). Periodic late-night salivary cortisol assessment in patients postoperatively would seem a simple and prudent approach to follow these patients. In two recent studies, an increased late-night salivary cortisol was considered a highly sensitive approach (90–100%) to detect a recurrence or surgical treatment failure in Cushing's disease (Fig. 2) (44, 57). Midnight salivary cortisol measurement performed as well as midnight plasma cortisol and is clearly easier to obtain. More importantly, 24-h urine free cortisol measurements had several false-negative results, confirming its lack of sensitivity for mild hypercortisolism (Fig. 2).

Cyclical or intermittent Cushing's syndrome

There are patients that, for pathophysiological reasons that are often unclear, have waxing and waning of their biochemical and clinical evidence of Cushing's syndrome (58–61). The assessment of late-night salivary cortisol over days, to weeks, to even years has been proposed as an efficient way to evaluate these patients (58–60). Furthermore, it is recommended that salivary cortisol be assessed the night before inferior petrosal sinus sampling for ACTH in the differential diagnosis of Cushing's disease and the occult ectopic ACTH syndrome to ensure that the testing is done when the ACTH-secreting tumor is active (62).

Summary of Cushing's syndrome

The measurement of late-night salivary cortisol, usually at 2300 to 2400 h, has proven to be a very useful




FIG. 2. A, Midnight plasma cortisol; B, midnight salivary cortisol; and C, 24-h urine free cortisol in postsurgical patients with Cushing's disease in remission compared with surgical failures. Each circle represents one patient. The dashed line corresponds to the cutoff of 75 ng/ml (207 nmol/liter) for midnight plasma cortisol (A), 2 ng/ml (5.52 nmol/liter) for midnight salivary cortisol (B), and 90 μ g/24 h (248 nmol/24 h) for urinary cortisol excretion (C). From Ref. 57 with permission.

approach to the diagnosis of Cushing's syndrome. Saliva can be sampled by patients at home and delivered or sent to the appropriate reference laboratory. It can also be sampled in hospitalized patients, but care should be taken to minimize stress in these circumstances. Late-night salivary cortisol sampling is also useful in assessing patients with suspected cyclical Cushing's syndrome as well as to follow patients after surgical treatment to monitor remission or recurrence.

Adrenal Insufficiency

Classic adrenal insufficiency has two general forms. Primary adrenal insufficiency is due to a failure of the adrenal gland to synthesize and release cortisol, usually due to an autoimmune or infectious process, and is also called Addison's disease (63). In secondary adrenal insufficiency, the adrenal cortex does not produce adequate cortisol because of a decrease in stimulation from pituitary ACTH. This can have many endogenous causes including infec-




FIG. 3. Measurement of serum (*left*) and salivary (*right*) cortisol in response to the low-dose ($1 \mu\text{g}$) ACTH₁₋₂₄ in normal subjects, patients with secondary adrenal insufficiency (hypoadrenal), and patients with increased CBG due to oral contraceptives or hormone replacement therapy (hyperoestrogenic). *, Hyperoestrogenic women had increased cortisol levels; #, hypoadrenal patients had lower cortisol than normal subjects. From Ref. 67 with permission.

tion, autoimmune destruction, and infarction of the anterior pituitary gland (64). The most common exogenous cause is suppression of the HPA axis by exogenous steroid use (64). There are also a variety of clinical situations where HPA axis suppression or relative suppression is a concern, such as in critical illness. Although, in general, the diagnosis of frank adrenal insufficiency is not as challenging as Cushing's syndrome, salivary cortisol measurements have been used to evaluate the HPA axis in situations of suspected decreased adrenal function.

Morning salivary cortisol

Because cortisol release peaks in the morning during the HPA axis circadian rhythm, it is theoretically possible that assessment of a subnormal morning cortisol might be diagnostic for adrenal insufficiency. The problem with morning cortisol assessment is the wide range of morning serum and salivary cortisol in normal subjects (43, 65, 66). Not surprisingly, measurements of basal morning levels of salivary cortisol alone are not useful for the diagnosis of primary or secondary adrenal insufficiency (67). The sensitivity and specificity of the measurement of an 0800 h serum or salivary cortisol for primary adrenal insufficiency is less than 35% (43). Therefore, the measurement of morning salivary cortisol is not particularly useful by itself in the diagnosis of adrenal insufficiency.

ACTH stimulation test

The standardized ACTH stimulation test using synthetic ACTH₁₋₂₄ (cosyntropin, tetracosactrin) is the gold standard for evaluation of primary or secondary adrenal insufficiency (68). Briefly, the concept is that pharmacological stimulation of the adrenal gland will reveal either a primary decrease in adrenocortical function, or a decrease in adrenal sensitivity to ACTH due to prolonged loss of a corticotropic stimulus in secondary ad-

renal insufficiency. In the typical patient being evaluated as an outpatient, there is no theoretical advantage to saliva *vs.* serum sampling because proximal stress from blood drawing is not particularly relevant. The early studies of Laudat *et al.* (69) demonstrated that there was complete separation between ACTH-stimulated salivary and serum cortisol in patients with primary or secondary adrenal insufficiency compared with normal subjects. Because salivary cortisol is a much better estimate of serum free cortisol than serum total cortisol, measurement of salivary cortisol is particularly useful in patients with corticoste-

roid-binding globulin (CBG) deficiency (26) or with increased CBG levels found in pregnancy and in women on oral contraceptives (67, 70). However, Deutschbein *et al.* (71) recently demonstrated that assessment of salivary cortisol did not perform as well as serum cortisol in the diagnosis of adrenal insufficiency during a standard ACTH stimulation test.

A modified, low-dose ACTH stimulation test has been advocated as an improved test primarily because it assesses adrenal sensitivity rather than maximum secretory capacity (72). Although the merits of this test are controversial (73–75), several investigators have attempted to use the measurement of salivary cortisol to assess the adrenal response to low-dose synthetic ACTH. It has recently been demonstrated that measuring salivary cortisol is useful during a low-dose ACTH stimulation test in children and adult patients with secondary adrenal insufficiency (Fig. 3) (67, 76). Also notice in Fig. 3 that salivary cortisol measured 30 min after injection of ACTH was able to demonstrate normal adrenal function in hyperoestrogenic women with increased serum cortisol, presumably due to increased serum binding proteins. Finally, Contreras *et al.* (77) developed a low-dose im ACTH stimulation test with assessment of salivary cortisol that does not require venous access. One can imagine, then, the ACTH stimulation test being performed in a variety of venues with the only requirements being an im injection of ACTH and the ability to sample saliva.

Monitoring glucocorticoid replacement

Another challenge in clinical endocrinology is how to monitor patients with adrenal insufficiency for adequate but not overreplacement of exogenous cortisol (hydrocortisone) therapy. In general, it has been found that monitor-

ing salivary cortisol does not add significantly to the evaluation of adequate glucocorticoid replacement (78–82).

Critical illness

A major controversy spanning several specialties is the overuse of glucocorticoids in critically ill patients (83). Most of these patients do not have frank adrenal insufficiency, but they may have a lower total plasma cortisol level than expected for the degree of illness in part due to lower plasma binding proteins including CBG (84). Arafah *et al.* (85) have demonstrated that ACTH-stimulated salivary cortisol release correlated well with serum free cortisol levels in critically ill patients. We recently demonstrated that ACTH-stimulated salivary cortisol measurements can help avoid the unnecessary use of glucocorticoid therapy in hospitalized patients (86). Other examples of the usefulness of salivary cortisol measurements in chronic illness are in the evaluation of patients with end-stage renal disease and HIV infection (87, 88).

Summary of adrenal insufficiency

A random morning salivary or serum cortisol measurement is not a particularly useful method to make the diagnosis of adrenal insufficiency of any etiology. The measurement of salivary cortisol during an ACTH stimulation test may have some advantages over serum, particularly in patients with an increase in CBG levels due to pregnancy or estrogen therapy and decreased CBG levels due to critical illness. An exciting application of this approach is in ACTH injection with salivary cortisol measurement to evaluate adrenal function in the field. It may even be possible some day to measure salivary cortisol after ACTH injection in climbers on Mount Everest.

Summary

The advent of assay methods to measure steroids in small volumes of saliva has led to many new studies that have evaluated salivary cortisol for the diagnosis of pituitary-adrenal disorders. Clearly, the use of late-night salivary cortisol measurements in the diagnosis of Cushing's syndrome shows great promise and will probably supplant older more cumbersome testing over the next decade. The use of salivary cortisol measurements in the diagnosis of adrenal insufficiency is not as established and probably does not offer a major advance except in situations where venous sampling is difficult or plasma binding proteins are altered. It will be exciting to see many more studies evaluating this technology, and it is expected that the measurement of salivary cortisol will soon become routine in clinical practice for the evaluation of disorders of the HPA axis.

Acknowledgments

Address all correspondence and requests for reprints to: Hershel Raff, Ph.D., St. Luke's Physician's Office Building, 2801 West KK River Parkway, Suite 245, Milwaukee Wisconsin 53215. E-mail: hraff@mcw.edu.

Disclosure Summary: The author has nothing to disclose.

References

1. Raff H, Findling JW 2003 A physiologic approach to diagnosis of the Cushing syndrome. *Ann Intern Med* 138:980–991
2. Kirschbaum C, Hellhammer DH 1994 Salivary cortisol in psychoneuroendocrine research: recent developments and applications. *Psychoneuroendocrinology* 19:313–333
3. Hellhammer DH, Wüst S, Kudielka BM 2009 Salivary cortisol as a biomarker in stress research. *Psychoneuroendocrinology* 34:163–171
4. Carroll T, Raff H, Findling JW 2008 Late-night salivary cortisol measurement in the diagnosis of Cushing's syndrome. *Nat Clin Pract Endocrinol Metab* 4:344–350
5. Findling JW, Raff H 2006 Cushing's syndrome: important issues in diagnosis and management. *J Clin Endocrinol Metab* 91:3746–3753
6. Findling JW, Raff H 2001 Diagnosis and differential diagnosis of Cushing's syndrome. *Endocrinol Metab Clin North Am* 30:729–747
7. Findling JW, Raff H 1999 Newer diagnostic techniques and problems in Cushing's disease. *Endocrinol Metab Clin North Am* 28:191–210
8. Gröschl M 2008 Current status of salivary hormone analysis. *Clin Chem* 54:1759–1769
9. Lewis JG 2006 Steroid analysis in saliva: an overview. *Clin Biochem Rev* 27:139–146
10. Findling JW, Raff H 2005 Screening and diagnosis of Cushing's syndrome. *Endocrinol Metab Clin North Am* 34:385–402
11. Wood P 2009 Salivary steroid assays—research or routine? *Ann Clin Biochem* 46:183–196
12. Gröschl M, Rauh M 2006 Influence of commercial collection devices for saliva on the reliability of salivary steroid analysis. *Steroids* 71:1097–1100
13. Shirtcliff EA, Granger DA, Schwartz E, Curran MJ 2001 Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results. *Psychoneuroendocrinology* 26:165–173
14. Kidd S, Midgley P, Lone N, Wallace AM, Nicol M, Smith J, McIntosh N 2009 A re-investigation of saliva collection procedures that highlights the risk of potential positive interference in cortisol immunoassay. *Steroids* 74:666–668
15. Hansen AM, Garde AH, Persson R 2008 Measurement of salivary cortisol—effects of replacing polyester with cotton and switching antibody. *Scand J Clin Lab Invest* 68:826–829
16. Poll EM, Kreitschmann-Andermahr I, Langejuergen Y, Stanzel S, Gilsbach JM, Gressner A, Yagmur E 2007 Saliva collection method affects predictability of serum cortisol. *Clin Chim Acta* 382:15–19
17. Broderick JE, Arnold D, Kudielka BM, Kirschbaum C 2004 Salivary cortisol sampling compliance: comparison of patients and healthy volunteers. *Psychoneuroendocrinology* 29:636–650
18. Garde AH, Hansen AM 2005 Long-term stability of salivary cortisol. *Scand J Clin Lab Invest* 65:433–436
19. Gröschl M, Wagner R, Rauh M, Dörr HG 2001 Stability of salivary steroids: the influences of storage, food and dental care. *Steroids* 66:737–741
20. Clements AD, Parker CR 1998 The relationship between salivary

- cortisol concentrations in frozen versus mailed samples. *Psychoneuroendocrinology* 23:613–616
21. Kivlighan KT, Granger DA, Schwartz EB, Nelson V, Curran M, Shirtcliff EA 2004 Quantifying blood leakage into the oral mucosa and its effects on the measurement of cortisol, dehydroepiandrosterone, and testosterone in saliva. *Horm Behav* 46:39–46
 22. Hansen AM, Garde AH, Christensen JM, Eller NH, Netterstrøm B 2003 Evaluation of a radioimmunoassay and establishment of a reference interval for salivary cortisol in healthy subjects in Denmark. *Scand J Clin Lab Invest* 63:303–310
 23. Baid SK, Sinaii N, Wade M, Rubino D, Nieman LK 2007 Radioimmunoassay and tandem mass spectrometry measurement of bedtime salivary cortisol levels: a comparison of assays to establish hypercortisolism. *J Clin Endocrinol Metab* 92:3102–3107
 24. Vogeser M, Durner J, Seliger E, Auernhammer C 2006 Measurement of late-night salivary cortisol with an automated immunoassay system. *Clin Chem Lab Med* 44:1441–1445
 25. Raff H, Homar PJ, Burns EA 2002 Comparison of two methods for measuring salivary cortisol. *Clin Chem* 48:207–208
 26. Perogamyros I, Owen LJ, Keevil BG, Brabant G, Trainer PJ 19 March 2009 Measurement of salivary cortisol with liquid chromatography-tandem mass spectrometry in patients undergoing dynamic endocrine testing. *Clin Endocrinol (Oxf)* 10.1111/j.1365-2265.2009.03582.x
 27. Garde AH, Hansen AM, Nikolajsen TB 2003 An inter-laboratory comparison for determination of cortisol in saliva. *Accred Qual Assur* 8:16–20
 28. Raff H, Homar PJ, Skoner DP 2003 New enzyme immunoassay for salivary cortisol. *Clin Chem* 49:203–204
 29. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M 2003 Diagnosis and complications of Cushing's syndrome: a consensus statement. *J Clin Endocrinol Metab* 88:5593–5602
 30. Aron DC, Findling JW, Tyrrell JB 1987 Cushing's disease. *Endocrinol Metab Clin North Am* 16:705–730
 31. Aron DC, Tyrrell JB, Fitzgerald PA, Findling JW, Forsham PH 1981 Cushing's syndrome: problems in diagnosis. *Medicine (Baltimore)* 60:25–35
 32. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. *J Clin Endocrinol Metab* 93:1553–1562
 33. Kola B, Grossman AB 2008 Dynamic testing in Cushing's syndrome. *Pituitary* 11:155–162
 34. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM 2008 The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 93:1526–1540
 35. Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M 1995 A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. *Clin Endocrinol (Oxf)* 43:545–550
 36. Papanicolaou DA, Yanovski JA, Cutler Jr GB, Chrousos GP, Nieman LK 1998 A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states. *J Clin Endocrinol Metab* 83:1163–1167
 37. Evans PJ, Peters JR, Dyas J, Walker RF, Riad-Fahmy D, Hall R 1984 Salivary cortisol levels in true and apparent hypercortisolism. *Clin Endocrinol (Oxf)* 20:709–715
 38. Castro M, Elias LL, Elias PC, Moreira AC 2003 A dose-response study of salivary cortisol after dexamethasone suppression test in Cushing's disease and its potential use in the differential diagnosis of Cushing's syndrome. *Clin Endocrinol (Oxf)* 59:800–805
 39. Castro M, Elias PC, Quidute AR, Halah FP, Moreira AC 1999 Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. *J Clin Endocrinol Metab* 84:878–882
 40. Cardoso EM, Arregger AL, Tumilasci OR, Contreras LN 2009 Diagnostic value of salivary cortisol in Cushing's syndrome (CS). *Clin Endocrinol (Oxf)* 70:516–521
 41. Martinelli Jr CE, Sader SL, Oliveira EB, Daneluzzi JC, Moreira AC 1999 Salivary cortisol for screening of Cushing's syndrome in children. *Clin Endocrinol (Oxf)* 51:67–71
 42. Gafni RI, Papanicolaou DA, Nieman LK 2000 Nighttime salivary cortisol measurement as a simple, noninvasive, outpatient screening test for Cushing's syndrome in children and adolescents. *J Pediatr* 137:30–35
 43. Restituto P, Galofré JC, Gil MJ, Mugueta C, Santos S, Monreal JI, Varo N 2008 Advantage of salivary cortisol measurements in the diagnosis of glucocorticoid related disorders. *Clin Biochem* 41:688–692
 44. Nunes ML, Vattaut S, Corcuff JB, Rault A, Loiseau H, Gatta B, Valli N, Letenneur L, Tabarin A 2009 Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients. *J Clin Endocrinol Metab* 94:456–462
 45. Kidambi S, Raff H, Findling JW 2007 Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. *Eur J Endocrinol* 157:725–731
 46. Garde AH, Persson R, Hansen AM, Osterberg K, Ørbaek P, Eek F, Karlson B 2009 Effects of lifestyle factors on concentrations of salivary cortisol in healthy individuals. *Scand J Clin Lab Invest* 69:242–250
 47. Liu H, Bravata DM, Cabaccan J, Raff H, Ryzen E 2005 Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. *Clin Endocrinol (Oxf)* 63:642–649
 48. Carroll T, Raff H, Findling JW 2009 Late-night salivary cortisol for the diagnosis of Cushing's syndrome: a meta-analysis. *Endocr Pract* 15:335–342
 49. Terzolo M, Reimondo G, Bovio S, Angeli A 2004 Subclinical Cushing's syndrome. *Pituitary* 7:217–223
 50. Terzolo M, Pia A, Ali A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A 2002 Adrenal incidentaloma: a new cause of the metabolic syndrome? *J Clin Endocrinol Metab* 87:998–1003
 51. Terzolo M, Osella G, Ali A, Borretta G, Cesario F, Paccotti P, Angeli A 1998 Subclinical Cushing's syndrome in adrenal incidentaloma. *Clin Endocrinol (Oxf)* 48:89–97
 52. Terzolo M, Bovio S, Reimondo G, Pia A, Osella G, Borretta G, Angeli A 2005 Subclinical Cushing's syndrome in adrenal incidentalomas. *Endocrinol Metab Clin North Am* 34:423–439
 53. Terzolo M, Bovio S, Pia A, Osella G, Borretta G, Angeli A, Reimondo G 2007 Subclinical Cushing's syndrome. *Arq Bras Endocrinol Metabol* 51:1272–1279
 54. Masserini B, Morelli V, Bergamaschi S, Ermetici F, Eller-Vainicher C, Barbieri AM, Maffini MA, Scillitani A, Ambrosi B, Beck-Peccoz P, Chiodini I 2009 The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. *Eur J Endocrinol* 160:87–92
 55. Tsagarakis S, Vassiliadi D, Thalassinou N 2006 Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. *J Endocrinol Invest* 29:471–482
 56. Aghi MK, Petit J, Chapman P, Loeffler J, Klubanski A, Biller BM, Swearingen B 2008 Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery. *Clin Neurosurg* 55:141–144
 57. Carrasco CA, Coste J, Guignat L, Groussin L, Dugué MA, Gaillard S, Bertagna X, Bertherat J 2008 Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing's disease. *J Clin Endocrinol Metab* 93:4728–4734
 58. Meinardi JR, Wolffenbuttel BH, Dullaart RP 2007 Cyclic Cushing's syndrome: a clinical challenge. *Eur J Endocrinol* 157:245–254
 59. Hermus AR, Pieters GF, Borm GF, Verhofstad AA, Smals AG, Benraad TJ, Kloppenborg PW 1993 Unpredictable hypersecretion of

- cortisol in Cushing's disease: detection by daily salivary cortisol measurements. *Acta Endocrinol (Copenh)* 128:428–432
60. Mosnier-Pudar H, Thomopoulos P, Bertagna X, Fournier C, Guiban D, Luton JP 1995 Long-distance and long-term follow-up of a patient with intermittent Cushing's disease by salivary cortisol measurements. *Eur J Endocrinol* 133:313–316
 61. Alexandraki KI, Kaltsas GA, Isidori AM, Akker SA, Drake WM, Chew SL, Monson JP, Besser GM, Grossman AB 2009 The prevalence and characteristic features of cyclicality and variability in Cushing's disease. *Eur J Endocrinol* 160:1011–1018
 62. Javorsky B, Findling JW, Inferior petrosal sinus sampling for the differential diagnosis of ACTH-dependent Cushing's syndrome. In: Bronstein MD, ed. *Cushing's syndrome: pathophysiology, diagnosis, and treatment*. Totowa, NJ: Humana Press; in press
 63. Ten S, New M, Maclaren N 2001 Clinical review 130: Addison's disease 2001. *J Clin Endocrinol Metab* 86:2909–2922
 64. Reimondo G, Bovio S, Allasino B, Terzolo M, Angeli A 2008 Secondary hypoadrenalism. *Pituitary* 11:147–154
 65. Raff H, Raff JL, Findling JW 1998 Late-night salivary cortisol as a screening test for Cushing's syndrome. *J Clin Endocrinol Metab* 83:2681–2686
 66. Raff H 2000 Salivary cortisol: a useful measurement in the diagnosis of Cushing's syndrome and the evaluation of the hypothalamic-pituitary adrenal axis. *The Endocrinologist* 10:9–17
 67. Marcus-Perlman Y, Tordjman K, Greenman Y, Limor R, Shenkerman G, Osher E, Stern N 2006 Low-dose ACTH (1 microg) salivary test: a potential alternative to the classical blood test. *Clin Endocrinol Oxf* 64:215–218
 68. Grinspoon SK, Biller BM 1994 Clinical review 62: laboratory assessment of adrenal insufficiency. *J Clin Endocrinol Metab* 79:923–931
 69. Laudat MH, Cerdas S, Fournier C, Guiban D, Guilhaume B, Luton JP 1988 Salivary cortisol measurement: a practical approach to assess pituitary-adrenal function. *J Clin Endocrinol Metab* 66:343–348
 70. Suri D, Moran J, Hibbard JU, Kasza K, Weiss RE 2006 Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropic stimulation test. *J Clin Endocrinol Metab* 91:3866–3872
 71. Deutschbein T, Unger N, Mann K, Petersenn S 2009 Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test. *Eur J Endocrinol* 160:9–16
 72. Dickstein G, Shechner C, Nicholson WE, Rosner I, Shen-Orr Z, Adawi F, Lahav M 1991 Adrenocorticotropic stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. *J Clin Endocrinol Metab* 72:773–778
 73. Oelkers W, Tuschelt H 2001 Hypothalamo-pituitary-adrenal axis testing: nothing is sacred and caution in interpretation is needed. *Clin Endocrinol Oxf* 55:821–822
 74. Oelkers W 1998 The role of high- and low-dose corticotropin tests in the diagnosis of secondary adrenal insufficiency. *Eur J Endocrinol* 139:567–570
 75. Oelkers W 1996 Adrenal insufficiency. *N Engl J Med* 335:1206–1212
 76. Cetinkaya S, Ozon A, Yordam N 2007 Diagnostic value of salivary cortisol in children with abnormal adrenal cortex functions. *Horm Res* 67:301–306
 77. Contreras LN, Arregger AL, Persi GG, Gonzalez NS, Cardoso EM 2004 A new less-invasive and more informative low-dose ACTH test: salivary steroids in response to intramuscular corticotrophin. *Clin Endocrinol Oxf* 61:675–682
 78. Thomson AH, Devers MC, Wallace AM, Grant D, Campbell K, Freel M, Connell JM 2007 Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. *Clin Endocrinol Oxf* 66:789–796
 79. Løvås K, Husebye ES 2007 Continuous subcutaneous hydrocortisone infusion in Addison's disease. *Eur J Endocrinol* 157:109–112
 80. Løvås K, Thorsen TE, Husebye ES 2006 Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison's disease. *J Endocrinol Invest* 29:727–731
 81. Wong V, Yan T, Donald A, McLean M 2004 Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients. *Clin Endocrinol Oxf* 61:131–137
 82. Maguire AM, Ambler GR, Moore B, Waite K, McLean M, Cowell CT 2007 The clinical utility of alternative, less invasive sampling techniques in the assessment of oral hydrocortisone therapy in children and adolescents with hypopituitarism. *Eur J Endocrinol* 156:471–476
 83. Arafah BM 2006 Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. *J Clin Endocrinol Metab* 91:3725–3745
 84. Raff H, Findling JW 1990 Aldosterone control in critically ill patients: ACTH, metoclopramide, and atrial natriuretic peptide. *Crit Care Med* 18:915–920
 85. Arafah BM, Nishiyama FJ, Tlaygeh H, Hejal R 2007 Measurement of salivary cortisol concentration in the assessment of adrenal function in critically ill subjects: a surrogate marker of the circulating free cortisol. *J Clin Endocrinol Metab* 92:2965–2971
 86. Raff H, Brock S, Findling JW 2008 Cosyntropin-stimulated salivary cortisol in hospitalized patients with hypoproteinemia. *Endocrine* 34:68–74
 87. Arregger AL, Cardoso EM, Tumilasci O, Contreras LN 2008 Diagnostic value of salivary cortisol in end stage renal disease. *Steroids* 73:77–82
 88. Cardoso E, Persi G, González N, Tumilasci O, Arregger A, Burgos M, Rodríguez V, Molina A, Contreras LN 2007 Assessment of adrenal function by measurement of salivary steroids in response to corticotrophin in patients infected with human immunodeficiency virus. *Steroids* 72:328–334
 89. Luthold WW, Marcondes JA, Wajchenberg BL 1985 Salivary cortisol for the evaluation of Cushing's syndrome. *Clin Chim Acta* 151:33–39
 90. Papanicolaou DA, Mullen N, Kyrou I, Nieman LK 2002 Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. *J Clin Endocrinol Metab* 87:4515–4521
 91. Putignano P, Toja P, Dubini A, Pecori Giraldi F, Corsello SM, Cavagnini F 2003 Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome. *J Clin Endocrinol Metab* 88:4153–4157
 92. Yaneva M, Mosnier-Pudar H, Dugué MA, Grabar S, Fulla Y, Bertagna X 2004 Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. *J Clin Endocrinol Metab* 89:3345–3351
 93. Trilck M, Flitsch J, Lüdecke DK, Jung R, Petersenn S 2005 Salivary cortisol measurement—a reliable method for the diagnosis of Cushing's syndrome. *Exp Clin Endocrinol Diabetes* 113:225–230
 94. Viardot A, Huber P, Puder JJ, Zulewski H, Keller U, Müller B 2005 Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. *J Clin Endocrinol Metab* 90:5730–5736
 95. Vilar L, Freitas MC, Naves LA, Canadas V, Albuquerque JL, Botelho CA, Egito CS, Arruda MJ, Silva LM, Arahata CM, Agra R, Lima LH, Azevedo M, Casulari LA 2008 The role of non-invasive dynamic tests in the diagnosis of Cushing's syndrome. *J Endocrinol Invest* 31:1008–1013
 96. Doi M, Sekizawa N, Tani Y, Tsuchiya K, Kouyama R, Tateno T, Izumiyama H, Yoshimoto T, Hirata Y 2008 Late-night salivary cortisol as a screening test for the diagnosis of Cushing's syndrome in Japan. *Endocr J* 55:121–126
 97. Yaneva M, Kirilov G, Zacharieva S 2009 Midnight salivary cortisol, measured by highly sensitive electrochemiluminescence immunoassay, for the diagnosis of Cushing's syndrome. *Central Eur J Med* 4:59–64